The EMERALD trial (NCT03778931), is an open label phase 3 trial, investigating elacestrant, the first oral selective estrogen receptor degrader (SERD), against “standard of care”, in advanced or metastatic ER+/HER2- breast cancer patients [2]. The gene discussed is ESR1; the disease is breast cancer.